The purpose of this study is to determine if recurrent glioblastoma can be shrunk or stabilized by adding immune therapy drugs to the usual radiation therapy and if this approach is better or worse than the usual approach for recurrent glioblastoma (The usual approach is treatment with surgery, radiation, or chemotherapy.).
Learn more about the NRG-BN010 trial or call the Reading Hospital Cancer Research Office at 484-628-8193.
